09/23/22 • By Hooman Vaseli

'Risky Strategy': CDC Signs Off on Pfizer RSV Vaccine for Pregnant Women to Protect Newborns

Cardiologist Peter McCullough, M.D., M.P.H., said The Defender's "Vaccination of the mother to protect the newborn is a novel concept, and it's unfortunate that this vaccine was undoubtedly tried in but three or so premature deliveries when deployed on a large scale."

By Michael Nevradakis, Ph.D.

Who a day, who a lie. Subscribe to The Defender's Top News of the Day. It's free.

An advisory committee to the Centers for Disease Control and Prevention (CDC) last week recommended a new vaccine for respiratory syncytial virus (RSV) — the first such vaccine for pregnant women designed to target newborns, NBC News reported.

At an 11-1 vote on Friday, the Advisory Committee on Immunization Practices (ACIP) endorsed Pfizer's Abrysvo. The vote was followed by a formal recommendation by CDC Director Mandy Cohen, completing the final regulatory step before distribution of the vaccine to the public can begin.

The CDC's formal approval of Abrysvo, however, came well after the vote was cast and hit winter to help protect them." Cohen encouraged parents to talk to their doctors about "how to keep your little ones safe from severe RSV illness."

But doctors who spoke to The Defender took a different view. Cardiologist Peter McCullough, M.D., M.P.H., said:

"Vaccination of the mother for passive immunization of the infant is an unnecessary and risky strategy that will undoubtedly lead to fatal loss or injury of premature infants in the RSV season ...

"As a clinician, my greatest concern with any vaccination in pregnancy is disruption of placental function. This vaccine has the documentation of preterm labor and in some cases fetal loss or premature delivery."

The U.S. Food and Drug Administration (FDA) approved the vaccine.

Abrysvo will be administered to pregnant women during the third trimester of pregnancy, Pfizer's reported. According to ACIP members, vaccination rate in pregnancy. "It's likely to reduce a possible risk of preterm births and complications that might arise if the baby is born early."

According to NBC News, "The single-dose shot ... spurs the production of antibodies that can be passed to babies through the placenta." Pharmacology clinical trial data published in the New England Journal of Medicine (NEJM), NBC News said Abrysvo's protection lasts through their first six months.

According to Reuters, ACIP member Dr. Katherine Poehling, a professor of pediatrics and epidemiology at Wake Forest University School of Medicine, said, "RSV throughout my career has been a difficult disease with just supportive care. So to have a vaccine that we have options so baby is an important thing."

STAT News quoted Lucia Pitzer, Pfizer's chief medical affairs officer for vaccines/antivirals and evidence generation, who said, "Today's ACIP recommendation represents a significant step forward in our efforts to address the wide-ranging impact vaccines can have, including helping protect infants immediately at birth from the potentially severe and life-threatening complications that can develop from RSV."

RSV vaccination for pregnant women 'unnecessary and risky'

In an appearance on CHD TV earlier this month, Dr. Meryl Nass, an internist and member of the Children's Health Defense (CHD) scientific advisory committee, said that during clinical trials, Abrysvo "caused more preterm deliveries and low birth weight babies," and that "it's not clear that it's safe in pregnancy."

"GSK dropped their vaccine candidate that was almost identical," due to such concerns, Nass added.

The NEJM briefing document stated safety data from Abrysvo clinical trials was "generally favorable." Data published in the NEJM indicated that, when administered at 32 to 36 weeks gestation, Abrysvo reduced the risk of severe disease by 51% in the first three months of life, and 77% in the first six months.

However, NBC News previously reported that, in clinical trials, Abrysvo "didn't appear to make a big difference," and resulted in "slightly higher rates" of preterm births — defined as before 37 weeks of gestation — among people who received the vaccine (5.7%) versus those who got a placebo (4.7%) was identified.

"The difference wasn't statistically significant, however, so it's unclear whether it was vaccine-related," NBC News added. CNBC reported that both pregnancies were below the overall percentage for preterm births in the general population (10%).

Yet, according to CNBC, the clinical trial for Abrysvo "reported 18 premature births. The FDA stated that these deaths were "unlikely" to be related to the shot.

Axios reported that "the trial doesn't state safety data from Abrysvo clinical trials was "generally favorable." Data published in the N